POSTPONED | Ad Astra Fellow Seminar Series
As part of the national efforts to manage the current COVID-19 Public Health Emergency, this event has been postponed. The seminar series will be re-scheduled at a later date.
The UCD School of Medicine is proud to introduce our Ad Astra Fellows through a seminar series in which each of our newest academic colleagues wll present an overview of their research interests.
Dr Sergio Rey who will present a seminar entitled 'Oxygen Sensing in Cancer' and Dr Luana Schito will present a seminar entitled Hypoxia and Metabolic Reprogramming in Cancer''.
These seminars will take place on Friday 27th March 2020 at 1pm in C006, UCD Health Sciences Centre, Belfield.
All academic staff are cordially invited to attend these seminars and welcome their new University colleagues.
More seminars in the UCD Ad Astra Fellow Seminar Series
About Our Speakers
Dr Sergio Rey
Dr. Rey is a Chilean-born Canadian physician-scientist with more than two decades of experience dedicated to the delineation of molecular mechanisms enacting oxygen sensing in human health and disease. After receiving separate MD (2001) and PhD (2006) degrees by the Pontifical Catholic University of Chile, he engaged in back-to-back postdoctoral training with Nobel laureate Dr. Gregg L. Semenza (2011) and renowned cancer geneticist Dr. Bert Vogelstein, at the Johns Hopkins University School of Medicine. In 2013 he moved to Toronto, Canada, wherein he has focused on uncovering novel molecular mechanisms by which oxygen governs cancer progression, leading to metastatic disease, therapy resistance and ultimately, mortality.
He is the recipient of a Young Investigator Award from the Wound Healing Society (2011); followed by two awards from the American Association for Cancer Research [i.e., Takeda Oncology (2016) and Minorities in Cancer Research (2017)]. Whilst contributing in the training of undergraduate and graduate biomedical students, he has collaborated with industry in the search for translatable oxygen- sensitive cancer therapeutics. His overarching long-term goal is to deconvolve the intricate molecular machinery underlying oxygen, or lack thereof (hypoxia), as a pathobiological scaffold guiding cancer progression, potentially leading to the development of safer and more effective targeted oncolytic therapies. [more]
Dr Luana Schito
Also recruited from the Princess Margaret Cancer Centre in Toronto, Dr. Schito is an Italian-born Canadian scientist who has devoted more than 14 years of effort in delineating the adaptive, pathophysiological responses of human cancer and their metastases to low oxygen (i.e., hypoxia). Dr. Schito obtained a M.Sc. in Molecular Biology (2007), followed by a Ph.D. in Human Pathology (2011) from the University of Rome Sapienza; the latter whilst performing her experimental thesis work under the mentorship of Nobel laureate Dr. Gregg L. Semenza at the Johns Hopkins University School of Medicine. She followed-up with postdoctoral training with Dr. Semenza until her move to Toronto, Canada (2013), wherein she has focused on uncovering novel molecular mechanisms by which tumor hypoxia drives resistance to radio- and chemotherapy in cancer patients. A particular research interest of hers is the utilization of top-down and bottom-up approaches to dissect the molecular correlates of hypoxic lymphatic dissemination in solid cancers, utilizing models of advanced disease.
Dr Schito is the recipient of the Women in Cancer Research Award (2016) from the American Association for Cancer Research (AACR) and the New Investigator Review Award (2018) from the American Physiological Society, among other recognitions. Dr. Schito has been actively involved in science outreach and fundraising, by serving in the AACR-Associate Member Council (2016) and engaging with the American Society for Cell Biology in an effort to promote research reproducibility, robustness and accountability in the Biomedical Sciences. The long-term objective of her research program is to enhance our understanding of the role of hypoxia as an organizing molecular principle in cancer pathophysiology, thus holding the promise of generating knowledge leading into effective treatments, designed to forestall or eradicate the disease. [more]